6-Methoxy-2-naphthylacetic acid prodrugs

ABSTRACT

The present invention provides therapeutically effective amounts of  6 MNA prodrugs. The pharmaceutical composition comprises  
                 
 
wherein R is H or COR′, wherein R′ is selected from the group consisting of C 1  to C 6  alkyl, (CH 2 ) m  O(CH 2 ) n , (CH 2 ) m (OC 2 H 4 ) p  O(CH 2 ) n , (CH 2 ) m (OC 2 H 4 ) p , (OCH 2 H 4 ) p  ONO 2  and (OCH 2 H 4 ) p  O(CH 2 ) n  wherein m is an integer from 2 to 4, and n and p are integers from 1 to 4. Alternatively, R is a therapeutic moiety.

RELATED APPLICATION

The present application is a continuation of U.S. application Ser. No.09/697,795, filed Oct. 27, 2000, which claims priority from U.S.Provisional Application 60/161,864, filed Oct. 27, 1999, the disclosuresof which are incorporated by reference herein in their entireties.

FIELD AND BACKGROUND OF THE INVENTION

The present invention relates to pharmaceutical compositions useful fortreatment of inflammation in humans utilizing compounds that areprodrugs of 6-methoxy-2-naphthylacetic acid (hereinafter “6MNA”).

Various naphthalene derivatives are known to be useful for the treatmentof inflammation and for various rheumatic and arthritic conditions. Forexample, Naproxen having the formula (I):

as described in U.S. Pat. No. 4,009,197 to Fried et al. Compound (I)can, however, cause severe irritation of the gastronintestinal tract atdosages only slightly greater than the excess of the therapeutic dose.

Another naphthalene derivative is nabumetone having the formula (II):

as described in U.S. Pat. Nos. 4,061,779 and 4,420,639 to Lake et al.Nabumetone works by inhibiting cyclooxygenase, an enzyme responsible formaking prostaglandins which are mediators of inflammation. Nabumetone isa prodrug which undergoes hepatic biotransformation to the activecomponent, 6-methoxy-2-naphthylacetic acid, Formula (III):

(See Haddock, R. E. et al; Metabolism of Nabumetone (BRL 14777 byvarious species including man,” Xenobiotica; 14(4): 327-337 (1984)).Nabumetone is commercially available as Relafen® from SmithklineBeecham, Inc. However, only about 35 percent of orally administerednabumetone is transferred in vivo into 6MNA.

It is therefore an object of the present invention to provide 6MNAprodrugs which are more readily transformed into 6MNA than nabumetone.It is believed that improvement in the body's ability to hydrolyze andsolubilize the prodrug can contribute to this transformation. Thus, itis another object to improve the hydrolysis and solubility of theprodrug to provide better transformation to 6MNA.

Another concern with 6MNA and its related prodrugs is that the presenceof the carboxylic acid moiety can cause stomach irritation and/orulceration. Thus, it is another object of the present invention thatprovides prodrugs of 6MNA having a reduced propensity to cause stomachirritation.

SUMMARY OF THE INVENTION

As discussed above, the present invention provides therapeuticallyeffective amounts of 6MNA prodrugs. It is believed that the 6MNA prodrugof the invention has improved hydrolysis and solubility. It is believedthat the prodrugs of the invention are useful for the treatment ofinflammation in humans, and can provide analgesic and antipyreticproperties.

The pharmaceutical composition comprises

wherein R is selected from the group consisting of H and COR′, whereinR′ is selected from the group consisting of C₁ to C₆ alkyl, (CH₂)_(m)O(CH₂)_(n), (CH₂)_(m)(OC₂H₄)_(p) O(CH₂)_(n), (CH₂)_(m)(OC₂H₄)_(p),(OCH₂H₄)_(p) ONO₂ and (OCH₂H₄)_(p) O(CH₂)_(n) wherein m is an integerfrom 2 to 4, and n and p are integers from 1 to 4. Alternatively, R is atherapeutic moiety.

The foregoing and other aspects of the present invention are explainedin detail in the detailed description and example set forth below.

BRIEF DESCRIPTION OF THE FIGURE

FIG. 1 is a graph of in plasma levels of Example 1 compared toNabumetone.

DETAILED DESCRIPTION OF THE INVENTION

The present invention will now be described more fully hereinafter. Thisinvention may, however, be embodied in different forms and should not beconstrued as limited to the embodiments set forth herein. Rather, theseembodiments are provided so that this disclosure will be thorough andcomplete, and will fully convey the scope of the invention to thoseskilled in the art.

The terminology used in the description of the invention herein is forthe purpose of describing particular embodiments only and is notintended to be limiting of the invention. As used in the description ofthe invention and the appended claims, the singular forms “a”, “an” and“the” are intended to include the plural forms as well, unless thecontext clearly indicates otherwise.

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. All publications, patentapplications, patents, and other references mentioned herein areincorporated by reference in their entirety.

A “therapeutically effective amount” is an amount necessary to prevent,delay or reduce the severity of inflammation and also includes an amountnecessary to enhance normal physiological functioning.

As used herein, a “pharmaceutically acceptable” component (such as asalt, carrier, excipient or diluent) of a formulation according to thepresent invention is a component which (1) is compatible with the otheringredients of the formulation in that it can be combined with the 6MNAprodrugs of the present invention without eliminating the biologicalactivity of the 6MNA prodrugs; and (2) is suitable for use with ananimal (e.g., a human) without undue adverse side effects, such astoxicity, irritation, and allergic response. Side effects are “undue”when their risk outweighs the benefit provided by the pharmaceuticalcomposition.

In one embodiment, the pharmaceutical composition is

wherein R is selected from the group consisting of is H and COR′ whereinR′ is selected from the group consisting of C, to C₆ alkyl, (CH₂)_(m)O(CH₂)_(n), (CH₂)_(m)(OC₂H₄)_(p) O(CH₂)_(n), (CH₂)_(m)(0C₂H₄)_(p),(OCH₂H₄)_(p) ONO₂ and (OCH₂H₄)_(p) O(CH₂)_(n) wherein m is an integerfrom 2 to 4, and n and p are integers from 1 to 4.

In a preferred embodiment R is H, and such composition converts directlyto the active drug 6MNA.

In another embodiment, R is a therapeutic moiety such as

Such prodrug composition can advantageously be used to treatinflammation, and also provide analgesic and antipyretic properties.6MNA prodrugs of the present invention may optionally be administered inconjunction with other compounds useful in the treatment of inflammationor useful in treatment of other indications associated with inflammationsuch as pain. The other compounds may optionally be administeredconcurrently. As used herein, the word “concurrently” means sufficientlyclose in time to produce a combined effect (that is, concurrently may besimultaneously, or it may be two or more events occurring within a shorttime period before or after each other).

As used herein, the administration of two or more compounds “incombination” means that the two compounds are administered closelyenough in time that the presence of one alters the biological effects ofthe other. The two compounds may be administered simultaneously (i.e.,concurrently) or sequentially. Simultaneous administration may becarried out by mixing the compounds prior to administration, or byadministering the compounds at the same point in time but at differentanatomic sites or using different routes of administration.

The phrases “concurrent administration,” “administration incombination,” “simultaneous administration” or “administeredsimultaneously” as used herein, interchangeably mean that the compoundsare administered at the same point in time or immediately following oneanother. In the latter case, the two compounds are administered at timessufficiently close that the results observed are indistinguishable fromthose achieved when the compounds are administered at the same point intime.

The present invention is primarily concerned with the treatment of humansubjects, but the invention may also be carried out on animal subjects,particularly mammalian subjects such as mice, rats, dogs, cats,livestock and horses for veterinary purposes, and for drug screening anddrug development purposes.

The 6MNA prodrugs disclosed herein can, as noted above, be prepared inthe form of their pharmaceutically acceptable salts. Pharmaceuticallyacceptable salts are salts that retain the desired biological activityof the parent compound and do not impart undesired toxicologicaleffects. Examples of such salts are (a) acid addition salts formed withinorganic acids, for example hydrochloric acid, hydrobromic acid,sulfuric acid, phosphoric acid, nitric acid and the like; and saltsformed with organic acids such as, for example, acetic acid, oxalicacid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoicacid, methanesulfonic acid, p-toluenesulfonic acid,naphthalenedisulfonic acid, polygalacturonic acid, and the like; (b)salts formed from elemental anions such as chlorine, bromine, andiodine, and (c) salts derived from bases, such as ammonium salts, alkalimetal salts such as those of sodium and potassium, alkaline earth metalsalts such as those of calcium and magnesium, and salts with organicbases such as dicyclohexylamine and N-methyl-D-glucamine.

The 6MNA prodrugs described above may be formulated for administrationin a pharmaceutical carrier in accordance with known techniques. See,e.g., Remington, The Science And Practice of Pharmacy (9^(th) Ed. 1995).In the manufacture of a pharmaceutical formulation according to theinvention, the prodrug (including the physiologically acceptable saltsthereof) is typically admixed with, inter alla, an acceptable carrier.The carrier must, of course, be acceptable in the sense of beingcompatible with any other ingredients in the formulation and must not bedeleterious to the patient. The carrier may be a solid or a liquid, orboth, and is preferably formulated with the compound as a unit-doseformulation, for example, a tablet, which may contain from 0.01 or 0.5%to 95% or 99% by weight of the 6MNA prodrug. One or more 6MNA prodrugsmay be incorporated in the formulations of the invention, which may beprepared by any of the well known techniques of pharmacy consistingessentially of admixing the components, optionally including one or moreaccessory ingredients.

The formulations of the invention include those suitable for oral,rectal, topical, buccal (e.g., sub-lingual), vaginal, parenteral (e.g.,subcutaneous, intramuscular, intradermal, or intravenous), topical(i.e., both skin and mucosal surfaces, including airway surfaces) andtransdermal administration, although the most suitable route in anygiven case will depend on the nature and severity of the condition beingtreated and on the nature of the particular 6MNA prodrug which is beingused.

Formulations suitable for oral administration may be presented indiscrete units, such as capsules, cachets, lozenges, or tables, eachcontaining a predetermined amount of the 6MNA prodrug; as a powder orgranules; as a solution or a suspension in an aqueous or non-aqueousliquid; or as an oil-in-water or water-in-oil emulsion. Suchformulations may be prepared by any suitable method of pharmacy whichincludes the step of bringing into association the 6MNA prodrug and asuitable carrier (which may contain one or more accessory ingredients asnoted above). In general, the formulations of the invention are preparedby uniformly and intimately admixing the 6MNA prodrug with a liquid orfinely divided solid carrier, or both, and then, if necessary, shapingthe resulting mixture. For example, a tablet may be prepared bycompressing or molding a powder or granules containing the 6MNA prodrug,optionally with one or more accessory ingredients. Compressed tabletsmay be prepared by compressing, in a suitable machine, the compound in afree-flowing form, such as a powder or granules optionally mixed with abinder, lubricant, inert diluent, and/or surface active/dispersingagent(s). Molded tablets may be made by molding, in a suitable machine,the powdered compound moistened with an inert liquid binder.

Formulations suitable for buccal (sub-lingual) administration includelozenges comprising the 6MNA prodrug in a flavoured base, usuallysucrose and acacia or tragacanth; and pastilles comprising the compoundin an inert base such as gelatin and glycerin or sucrose and acacia.

Formulations of the present invention suitable for parenteraladministration comprise sterile aqueous and non-aqueous injectionsolutions of the 6MNA prodrug, which preparations are preferablyisotonic with the blood of the intended recipient. These preparationsmay contain anti-oxidants, buffers, bacteriostats and solutes whichrender the formulation isotonic with the blood of the intendedrecipient. Aqueous and non-aqueous sterile suspensions may includesuspending agents and thickening agents. The formulations may bepresented in unit\dose or multi-dose containers, for example sealedampoules and vials, and may be stored in a freeze-dried (lyophilized)condition requiring only the addition of the sterile liquid carrier, forexample, saline or water-for-injection immediately prior to use.Extemporaneous injection solutions and suspensions may be prepared fromsterile powders, granules and tablets of the kind previously described.For example, in one aspect of the present invention, there is providedan injectable, stable, sterile composition comprising a compound ofFormula (I), or a salt thereof, in a unit dosage form in a sealedcontainer. The compound or salt is provided in the form of alyophilizate which is capable of being reconstituted with a suitablepharmaceutically acceptable carrier to form a liquid compositionsuitable for injection thereof into a subject. The unit dosage formtypically comprises from about 10 mg to about 10 grams of the compoundor salt. When the compound or salt is substantially water-insoluble, asufficient amount of emulsifying agent which is physiologicallyacceptable may be employed in sufficient quantity to emulsify thecompound or salt in an aqueous carrier. One such useful emulsifyingagent is phosphatidyl choline.

Formulations suitable for rectal administration are preferably presentedas unit dose suppositories. These may be prepared by admixing the 6MNAprodrug with one or more conventional solid carriers, for example, cocoabutter, and then shaping the resulting mixture.

Formulations suitable for topical application to the skin preferablytake the form of an ointment, cream, lotion, paste, gel, spray, aerosol,or oil. Carriers which may be used include petroleum jelly, lanoline,polyethylene glycols, alcohols, transdermal enhancers, and combinationsof two or more thereof.

Formulations suitable for transdermal administration may be presented asdiscrete patches adapted to remain in intimate contact with theepidermis of the recipient for a prolonged period of time. Formulationssuitable for transdermal administration may also be delivered byiontophoresis (see, for example, Pharmaceutical Research 3 (6): 318(1986)) and typically take the form of an optionally buffered aqueoussolution of the 6MNA prodrug. Suitable formulations comprise citrate orbis\tris buffer (pH6) or ethanol/water and contain from 0.1 to 0.2Mactive ingredient.

The therapeutically effective dosage of any 6MNA prodrug, the use ofwhich is in the scope of present invention, will vary somewhat fromcompound to compound, and patient to patient, and will depend uponfactors such as the age and condition of the patient and the route ofdelivery. Such dosages can be determined in accordance with routinepharmacological procedures known to those skilled in the art.

The therapeutically effective dosage of any specific compound, the useof which is in the scope of present invention, will vary somewhat fromcompound to compound, and patient to patient, and will depend upon thecondition of the patient and the route of delivery. As a generalproposition, a dosage from about 0.1 to about 50 mg/kg will havetherapeutic efficacy, with all weights being calculated based upon theweight of the 6MNA prodrug, including the cases where a salt isemployed. Toxicity concerns at the higher level may restrict intravenousdosages to a lower level such as up to about 10 mg/kg, with all weightsbeing calculated based upon the weight of the active base, including thecases where a salt is employed. A dosage from about 10 mg/kg to about 50mg/kg may be employed for oral administration. Typically, a dosage fromabout 0.5 mg/kg to 5 mg/kg may be employed for intramuscular injection.The duration of the treatment is usually once per day for a period oftwo to three weeks or until the condition is essentially controlled.Lower doses given less frequently can be used prophylactically toprevent or reduce the incidence of recurrence of the infection.

EXAMPLE Example 1 Synthesis of 2-(6-Methoxy-naphthalen-2-yl)-ethanol

6-MNA (1 g, 0.0046 mol) was suspended in anhydrous THF and was cooledwith ice bath suspension BH3(1 M solution in THF, 5 ml) was added. Thereaction mixture was stirred for 3 hours then DI water and sodiumcarbonate added. THF was removed and aqueous phase extracted with ethylacetate then washed with water, dried over. Na2SO4, filteredconcentrated and dried via vacuum.

Yield 93%. Melting point 110-113° C. product was analyzed by elementalanalysis, IR, MS, NMR.

MS: 202.10

IR (cm⁻¹)

Elemental analysis: C 56.18; H 4.28; N 4.03

NMR 1H

Analysis of blood samples in rats after oral delivery showed aconversion of the compound of Example 1 to the active drug 6MNA. Example1 had a rat paw edema, % inhibition of 67.5 as compared to 60.0 forNabumetone. FIG. 1 shows higher plasma levels, with more rapid onset,are achieved with Example 1 as compared to Nabumetone.

Analysis of blood samples in rats after oral delivery showed aconversion of the compound of Example 1 to the active drug 6MNA.

The foregoing is illustrative of the present invention and is not to beconstrued as limiting thereof. The invention is defined by the followingclaims, with equivalents of the claims to be included therein.

1. A pharmaceutical composition useful for treatment of inflammation tohumans comprising a therapeutically effective amount of a compound ofthe formula:

wherein R is a therapeutic moiety.
 2. A method of treating inflammationcomprising administering a therapeutically effective amount of acompound of the formula:

wherein R is a therapeutic moiety.